Lv0
0 积分 2024-05-18 加入
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
20小时前
已完结
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
22小时前
已完结
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial
17天前
已完结
PDG12 Cost-Effectiveness Analysis of Olaparib for Metastatic Castration Resistant Prostate Cancer Patients with at Least one Mutation in Genes BRCA1, BRCA2, or ATM
2个月前
已关闭
KEYNOTE-859: a Phase III Study of Pembrolizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
2个月前
已关闭
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
4个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
4个月前
已完结
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
11个月前
已完结
皖公网安备34019202002308
